<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00169143</url>
  </required_header>
  <id_info>
    <org_study_id>LNH 03-39B</org_study_id>
    <nct_id>NCT00169143</nct_id>
  </id_info>
  <brief_title>Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma</brief_title>
  <official_title>Study of R-ACVBP Regimen Supported by Pegfilgrastim in Previously Untreated Patients Aged From 18 to 60 Years With High-Risk Diffuse Large B-Cell Lymphoma (Age-Adjusted Ipi &gt;or= 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lymphoma Study Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lymphoma Study Association</source>
  <brief_summary>
    <textblock>
      Evaluation of the efficacy of a single injection of Pegfilgrastim (6mg) administered at day 3
      of each cycle of R-ACVBP regimen during 4 cycles in patients with CD20+ diffuse large B-cell
      lymphoma presenting at least 2 adverse prognostic factor of the age-adjusted international
      prognostic index (Aa-IPI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II, multicentric, open-label, non-randomized study, evaluating the efficacy
      of a single injection of Pegfilgrastim (6mg) administered at day 3 of each cycle of R-ACVBP
      regimen during 4 cycles in patients aged 18 to 60 years with previously untreated CD20+
      diffuse large B-cell lymphoma presenting at least 2 adverse prognostic factor of the
      age-adjusted international prognostic index (Aa-IPI), and eligible for transplant.

      It is anticipated that 60 subjects will be enrolled over 2 years (from 2004 to 2006), in a
      group sequential manner one planned interim analysis.

      The duration of the treatment period is approximately 26 weeks and patients are followed
      until Death.

      The total Duration of the study is expected to be 2.5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date>January 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the optimal combined dose intensity of the drug regimen</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specific dose intensities, incidence of neutropenia and neutropenic fever, duration of severe neutropenia, complete response rate, event-free and overall survival</measure>
  </secondary_outcome>
  <enrollment>60</enrollment>
  <condition>Untreated CD20-Positive Large B-Cell Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab + ACVBP regimen plus Pegfilgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous stem cell transplant</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with histologically proven CD20+ diffuse large B cell lymphoma (WHO
             Classification).

          -  Age &gt;18 and &lt; 61 years, eligible for transplant.

          -  Patient not previously treated.

          -  With at least two prognostic factors of the Aa-IPI.

          -  With a minimum life expectancy of 3 months.

          -  Creatinin level ≤ 150mmol/l, total bilirubin level  30mmol/l and transaminases  2.5
             maximum normal level, unless abnormalities are related to the lymphoma.

          -  Neutrophils &gt; 1.5 G/l and platelets &gt; 100 G/l, unless if patient has a bone marrow
             infiltration.

          -  Negative HIV, HBV and HCV serologies  4 weeks (except after vaccination).

          -  Having previously signed a written informed consent.

        Exclusion Criteria:

          -  Any other histological type of lymphoma.

          -  Any history of treated or non-treated indolent lymphoma.

          -  Central nervous system or meningeal involvement by lymphoma.

          -  Contra-indication to any drug contained in the chemotherapy regimens.

          -  Any history of cancer during the last 5 years, with the exception of non-melanoma skin
             tumors or stage 0 (in situ) cervical carcinoma.

          -  Any serious active disease (according to the investigator’s decision).

          -  Treatment with any investigational drug within 30 days before planned first cycle of
             chemotherapy and during the study.

          -  Pregnant or lactating women or women of childbearing potential not currently
             practicing an adequate method of contraception.

          -  Adult patient under tutelage.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>61 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corinne Haioun, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Henri Mondor, Créteil, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie Clinique - CHU Le Bocage</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie - Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre-Bénite cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Nancy Brabois</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.gela.org</url>
    <description>Official site of the Groupe d'Etude des Lymphomes de l'Adulte (In french)</description>
  </link>
  <reference>
    <citation>Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ; International Pegfilgrastim 749 Study Group. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003 Jan;14(1):29-35.</citation>
    <PMID>12488289</PMID>
  </reference>
  <reference>
    <citation>Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002 Feb 1;20(3):727-31.</citation>
    <PMID>11821454</PMID>
  </reference>
  <reference>
    <citation>Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, Frankel S, Flinn I, Lovelace W, Hackett J, Liang BC. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol. 2003 Feb 1;21(3):514-9.</citation>
    <PMID>12560443</PMID>
  </reference>
  <reference>
    <citation>Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, Bosly A, Morel P, Nouvel C, Tilly H, Lederlin P, Sebban C, Brière J, Gaulard P, Reyes F. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol. 2000 Aug;18(16):3025-30.</citation>
    <PMID>10944137</PMID>
  </reference>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>September 6, 2006</last_update_submitted>
  <last_update_submitted_qc>September 6, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2006</last_update_posted>
  <keyword>Diffuse large B cell lymphoma</keyword>
  <keyword>Pegfilgrastim</keyword>
  <keyword>Autotransplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vindesine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

